Trevena, Inc. (TRVN - Free Report) was a big mover last session, as the company saw its shares nearly 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 19.19% in the past one-month time frame.
The company has seen two positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Trevena. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Trevena currently has a Zacks Rank #3 (Hold) while its Earnings ESPis negative.
Another player in the Medical sector is Exelixis, Inc. (EXEL), which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is TRVN going up? Or down? Predict to see what others think: Up or Down.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Trevena, Inc. (TRVN - Free Report) was a big mover last session, as the company saw its shares nearly 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 19.19% in the past one-month time frame.
The company has seen two positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Trevena. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Trevena currently has a Zacks Rank #3 (Hold) while its Earnings ESPis negative.
Another player in the Medical sector is Exelixis, Inc. (EXEL), which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is TRVN going up? Or down? Predict to see what others think: Up or Down.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TRVN - FREE